27
New pooled data from the ZUMA-7 and ALYCANTE studies show that Yescarta® delivers:
• 65% two-year overall survival
• ~45% event-free survival
• >55% complete responses at three months
• 61% 12-month response durability
Benefits were consistent across patients, including those ineligible for high-dose chemo and transplant.
Safety remained comparable between studies, and long-term quality of life improved steadily.
Researchers say the results reaffirm Yescarta as a leading second-line option for relapsed/refractory LBCL.